MBX · MBX Biosciences, Inc.
$62.00
-2.02% last session
End-of-day data · updated 2026-07-28
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-17.0
Dividend yield
—
Beta
—
Avg volume
1M
Employees
0K
2D change
—
5D change
-3.57%
10D change
-2.57%
30D change
17.19%
60D change
94.79%
MTD change
9.62%
YTD change
94.36%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MBX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-12
Latest call per bank · past 12 months
Barclays
Overweight$70.00
+12.9% vs priceUBS
Buy$60.00
-3.2% vs priceGoldman Sachs
Sell$18.00
-71.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-12 | Barclays | Maintains | Overweight | $66.00 → $70.00 |
| 2026-05-12 | Citizens | Maintains | Market Outperform | $76.00 → $86.00 |
| 2026-05-11 | Truist Securities | Maintains | Buy | $50.00 → $70.00 |
| 2026-01-28 | Barclays | Initiates | Overweight | $0.00 → $66.00 |
| 2026-01-16 | Guggenheim | Maintains | Buy | $77.00 → $88.00 |
| 2026-01-07 | UBS | Initiates | Buy | $0.00 → $60.00 |
| 2025-12-19 | Stifel | Maintains | Buy | $45.00 → $50.00 |
| 2025-12-04 | Goldman Sachs | Initiates | Sell | $0.00 → $18.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 32.6% above the 50-day MA ($45.29).
- Price vs 200-day MA: Trading 76.8% above the 200-day MA ($33.97).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.84) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($9.74) and high ($65.71).
MBX Price Chart
Loading chart for MBX…
Fundamentals
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.